(Received for publication October 19, 1939) For many years it has been known (1, 2, 3, 4) that at the time of the crisis in lobar pneumonia, or immediately thereafter, an excess of typespecific antibody can be demonstrated in the blood serum of the patient. While this phenomenon is not absolutely invariable, most observers have agreed that it occurs in the great majority of instances. Conversely, in cases going on to a fatal termination, where crisis does not occur, no type-specific antibody can be demonstrated in the patient's serum during the course of the disease. These facts have led to the belief that spontaneous recovery in lobar pneumonia is intimately related to the patient's capacity for producing type-specific antibody in such amount as to react with all the available antigen in the body and actually to appear in excess in the blood serum. Moreover, in recent years the phenomenon has been used as a quantitative guide to serum therapy, administration of therapeutic serum being continued until an excess of antibody could be demonstrated in the patient's serum.
Since the introduction of sulfanilamide and related compounds in the treatment of infections, there has arisen intense speculation as to their mode of action. In view of the fact that these drugs, while definitely bacteriostatic, are not bactericidal, it is obvious that the ordinary defenses of the body must play an essential role in the successful operation of the drug, and evidence has been accumulated to show that phagocytosis of bacteria is more effective after they have been exposed to the action of sulfanilamide. In addition, the r6le of humeral antibodies has been studied experimentally, and it is the conclusion of a number of investigators that the effectiveness of these drugs is considerably enhanced if they act in the presence of immune serum.
In Of the principal immune bodies which have been investigated in connection with lobar pneumonia, i.e. protective substances, agglutinins, and precipitins, we elected to study the latter. The precipitin reaction with specific soluble substance of pneumococcus has been the subject of extensive investigation by Heidelberger and his coworkers. That the type-specific precipitin and the agglutinin are the same antibody now seems to have been definitely proven (5) . Moreover, an exceedingly close correlation has been shown to exist (6) between this antibody and the mouse protecting power of immune serum. As Heidelberger and Kendall (7) have stated, " while other reactions are more delicate, the precipitin test is among the most specific and least subject to errors and technical difficulties." The appearance of precipitins in the blood serum of thirteen patients recovering from lobar pneumonia, eight of whom had received serum therapy, was found by Tillett and Francis (8) to coincide with the appearance of agglutinins. For these reasons the precipitin test with type-specific polysaccharide was used in this study, according to the same technique which has been used in this clinic as a routine method of determining the adequacy of serum therapy. 307 Table I .
RESULTS
Nineteen cases of lobar pneumonia treated with sulfapyridine were investigated for the appearance of type-specific antibodies . Altogether one hundred and twenty-seven samples of serum were tested by means of the precipitin reaction with specific polysaccharide. Of the nineteen cases, only four were shown to have an excess of type-specific antibody in the blood, and in these four the antibody did not appear at the time of, or immediately after, the " crisis " induced by sulfapyridine. As nearly as can be determined from the data, antibodies in these four cases were first detectable after about a week of normal temperature. A study of the fever curves in the whole series indicates that the temperature fell to normal following sulfapyridine therapy within twenty-four hours in nine cases, within forty-eight hours in six, and within seventy-two in four cases. The fall to normal in those cases developing antibodies occurred in twenty-four hours in two cases, and in forty-eight and seventy-two hours in the other two respectively-a result exactly comparable to the rest of the series. Moreover, the duration of disease before sulfapyridine therapy was begun was no greater in the cases which developed antibodies than in those which did not. 1 The specific polysaccharides used in these tests were kindly supplied by Dr. Michael Heidelberger, to whom thanks are due, not only for them, but for invaluable advice.
Seven other cases were studied but not included in the series listed above, because each received, in addition to the sulfapyridine, a certain amount of therapeutic antipneumococcus serum. Two of these were due to Type I pneumococcus and both promptly showed an excess of antibody after serum therapy; five were due to Type III, and, of these, three promptly showed an excess of antibody. DISCUSSION These observations indicate that in nearly eighty per cent of a small series of cases of lobar pneumonia treated with sulfapyridine recovery took place without the appearance of an excess of type-specific antibodies. In view of the fact that the production of an excess of antibodies has hitherto been regarded as an essential part of the mechanism of spontaneous recovery from pneumonia, it must be concluded that sulfapyridine has supplanted, at least to some degree, this part of the immune mechanism. There is no evidence, of course, that antibody production ceases to occur in the presence of sulfapyridine; on the contrary, it is highly probable that it occurs, at least to some extent. Such, indeed, is suggested by the fact that in the cases where antibody appeared in excess, it did so later than has been observed in untreated cases, implying that production has been going on at a slower rate, probably because the stimulus to antibody formation is lessened through the action of the drug on the invading organism. Moreover, this abnormally low rate of antibody formation may explain the well-known clinical finding that if treatment with sulfapyridine is stopped too soon, even if the patient has had no fever for several days, a recrudescence of the pneumonia may take place. Finally, these observations do not settle the question as to whether therapeutic antiserum should or should not be given along with the drug; they merely indicate that demonstrable antibodies are not essential to recovery.
SUMMARY AND CONCLUSIONS 1. Nineteen cases of lobar pneumonia treated with sulfapyridine were studied for the appearance of type-specific antibodies in the blood serum, as judged by the precipitin reaction with specific polysaccharide.
